Verified clinical failure with cefotaxime 1g for treatment of gonorrhoea in the Netherlands: A case report

Sexually Transmitted Infections

Volumn 90, Issue 7, 2014, Pages 513-514

  Van Dam, Alje P ^a,b   Van Ogtrop, Marc L ^b   Golparian, Daniel ^c   Mehrtens, Jan ^d   De Vries, Henry J C ^e,f   Unemo, Magnus ^c  

^a Public Health Laboratory   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^d Integral Physician Practice West   (Netherlands)

^e Amsterdam Health Service   (Netherlands)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; DRUG TREATMENT FAILURE; DYSURIA; EPSILOMETER TEST; GONORRHEA; HUMAN; MALE; MEN WHO HAVE SEX WITH MEN; NETHERLANDS; NUCLEIC ACID AMPLIFICATION; URETHRAL DISCHARGE; URETHRITIS; URINALYSIS; DRUG EFFECTS; INTRAMUSCULAR DRUG ADMINISTRATION; MALE HOMOSEXUALITY; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; TREATMENT FAILURE;

ADULT; ANTI-BACTERIAL AGENTS; CEFOTAXIME; CEFTRIAXONE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GONORRHEA; HOMOSEXUALITY, MALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; NETHERLANDS; TREATMENT FAILURE;

EID: 84910674698     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2014-051552     Document Type: Article

References (10)

1. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012;7:1401-22.
2. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011;55:3538-45.
3. Unemo M, Golparian D, Nicholas R, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012;56:1273-80.
4. Cámara J, Serra J, Ayats J, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012;67:1858-60.
5. Unemo M, Fasth O, Fredlund H, et al. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009;63:1142-51.
6. Lindberg R, Fredlund H, Nicholas R, et al. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother 2007;51:2117-22.
7. Harvengt C, Wauters G, Meunier H. Cefotaxime kinetics after multiple-dose intramuscular study in healthy volunteers. Chemotherapy 1981;27:173-8.
8. Patel IH, Weinfeld RE, Konikoff J, et al. Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents. Antimicrob Agents Chemother 1982;21:957-62.
9. Bignell C, Unemo M. European STI Guidelines Editorial Board. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013;24:85-92.
10. Heymans R, Bruisten SM, Golparian D, et al. Clonally related Neisseria gonorrhoeae isolates with decreased susceptibility to the extended-spectrum cephalosporin cefotaxime in Amsterdam, the Netherlands. Antimicrob Agents Chemother 2012;56:1516-22.